Drugs / BI 905677
last change Jul 2022 re-read 3 minutes ago

BI 905677

Developed for
neoplasm
Investigated by
Boehringer Ingelheim

Trials 1

20192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT03604445 Aug 2018 → Jul 2022 neoplasm Boehringer Ingelheim Terminated No outcome recorded Stop: Business

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as BI 905677 ClinicalTrials.gov intervention name — accepted as the source's own label NCT03604445 ↗